Harm reduction agencies as a potential site for buprenorphine treatment

Aaron D. Fox, Adam Chamberlain, Taeko Frost, Chinazo O. Cunningham

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background: Harm reduction agencies complement addiction treatment by providing diverse services that improve the health of people who use drugs. Buprenorphine maintenance treatment (BMT) is an effective opioid addiction treatment that may be provided from flexible settings, potentially including harm reduction agencies. This study investigated attitudes toward different potential sites for BMT (harm reduction agencies, general medical clinics, and drug treatment programs) among harm reduction clients. Methods: Using computer-based interviews, participants indicated preferred potential site for BMT (harm reduction agency, drug treatment program, or general medical clinic), interest in BMT by potential site, motivation for treatment, and barriers to BMT. Multivariable logistic regression was used to determine factors associated with harm reduction agency preference. Results: Of 102 opioid users, the most preferred potential site for BMT was a harm reduction agency (51%), whereas fewer preferred general medical clinics (13%), drug treatment programs (12%), or were not interested in BMT (25%). In multivariable analysis, experiencing ≥1 barrier to BMT was strongly associated with preferring harm reduction agencies (adjusted odds ratio [aOR] = 3.39, 95% confidence interval [CI]: 1.00-11.43). Conclusions: The potential to initiate BMT at harm reduction agencies is highly favorable among harm reduction clients, especially among those experiencing barriers to BMT. Offering BMT at harm reduction agencies could improve access to treatment, but studies are needed to determine safety and efficacy of this approach.

Original languageEnglish (US)
Pages (from-to)155-160
Number of pages6
JournalSubstance Abuse
Volume36
Issue number2
DOIs
StatePublished - Apr 3 2015

Fingerprint

Harm Reduction
Buprenorphine
Pharmaceutical Preparations
Opioid Analgesics
Health Services
Motivation
Logistic Models
Odds Ratio

Keywords

  • Access to care
  • buprenorphine
  • harm reduction agencies
  • opioid addiction

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Psychiatry and Mental health

Cite this

Harm reduction agencies as a potential site for buprenorphine treatment. / Fox, Aaron D.; Chamberlain, Adam; Frost, Taeko; Cunningham, Chinazo O.

In: Substance Abuse, Vol. 36, No. 2, 03.04.2015, p. 155-160.

Research output: Contribution to journalArticle

@article{1a7b4c98816942c49d7869dbc235d882,
title = "Harm reduction agencies as a potential site for buprenorphine treatment",
abstract = "Background: Harm reduction agencies complement addiction treatment by providing diverse services that improve the health of people who use drugs. Buprenorphine maintenance treatment (BMT) is an effective opioid addiction treatment that may be provided from flexible settings, potentially including harm reduction agencies. This study investigated attitudes toward different potential sites for BMT (harm reduction agencies, general medical clinics, and drug treatment programs) among harm reduction clients. Methods: Using computer-based interviews, participants indicated preferred potential site for BMT (harm reduction agency, drug treatment program, or general medical clinic), interest in BMT by potential site, motivation for treatment, and barriers to BMT. Multivariable logistic regression was used to determine factors associated with harm reduction agency preference. Results: Of 102 opioid users, the most preferred potential site for BMT was a harm reduction agency (51{\%}), whereas fewer preferred general medical clinics (13{\%}), drug treatment programs (12{\%}), or were not interested in BMT (25{\%}). In multivariable analysis, experiencing ≥1 barrier to BMT was strongly associated with preferring harm reduction agencies (adjusted odds ratio [aOR] = 3.39, 95{\%} confidence interval [CI]: 1.00-11.43). Conclusions: The potential to initiate BMT at harm reduction agencies is highly favorable among harm reduction clients, especially among those experiencing barriers to BMT. Offering BMT at harm reduction agencies could improve access to treatment, but studies are needed to determine safety and efficacy of this approach.",
keywords = "Access to care, buprenorphine, harm reduction agencies, opioid addiction",
author = "Fox, {Aaron D.} and Adam Chamberlain and Taeko Frost and Cunningham, {Chinazo O.}",
year = "2015",
month = "4",
day = "3",
doi = "10.1080/08897077.2015.1011820",
language = "English (US)",
volume = "36",
pages = "155--160",
journal = "Substance Abuse",
issn = "0889-7077",
publisher = "Routledge",
number = "2",

}

TY - JOUR

T1 - Harm reduction agencies as a potential site for buprenorphine treatment

AU - Fox, Aaron D.

AU - Chamberlain, Adam

AU - Frost, Taeko

AU - Cunningham, Chinazo O.

PY - 2015/4/3

Y1 - 2015/4/3

N2 - Background: Harm reduction agencies complement addiction treatment by providing diverse services that improve the health of people who use drugs. Buprenorphine maintenance treatment (BMT) is an effective opioid addiction treatment that may be provided from flexible settings, potentially including harm reduction agencies. This study investigated attitudes toward different potential sites for BMT (harm reduction agencies, general medical clinics, and drug treatment programs) among harm reduction clients. Methods: Using computer-based interviews, participants indicated preferred potential site for BMT (harm reduction agency, drug treatment program, or general medical clinic), interest in BMT by potential site, motivation for treatment, and barriers to BMT. Multivariable logistic regression was used to determine factors associated with harm reduction agency preference. Results: Of 102 opioid users, the most preferred potential site for BMT was a harm reduction agency (51%), whereas fewer preferred general medical clinics (13%), drug treatment programs (12%), or were not interested in BMT (25%). In multivariable analysis, experiencing ≥1 barrier to BMT was strongly associated with preferring harm reduction agencies (adjusted odds ratio [aOR] = 3.39, 95% confidence interval [CI]: 1.00-11.43). Conclusions: The potential to initiate BMT at harm reduction agencies is highly favorable among harm reduction clients, especially among those experiencing barriers to BMT. Offering BMT at harm reduction agencies could improve access to treatment, but studies are needed to determine safety and efficacy of this approach.

AB - Background: Harm reduction agencies complement addiction treatment by providing diverse services that improve the health of people who use drugs. Buprenorphine maintenance treatment (BMT) is an effective opioid addiction treatment that may be provided from flexible settings, potentially including harm reduction agencies. This study investigated attitudes toward different potential sites for BMT (harm reduction agencies, general medical clinics, and drug treatment programs) among harm reduction clients. Methods: Using computer-based interviews, participants indicated preferred potential site for BMT (harm reduction agency, drug treatment program, or general medical clinic), interest in BMT by potential site, motivation for treatment, and barriers to BMT. Multivariable logistic regression was used to determine factors associated with harm reduction agency preference. Results: Of 102 opioid users, the most preferred potential site for BMT was a harm reduction agency (51%), whereas fewer preferred general medical clinics (13%), drug treatment programs (12%), or were not interested in BMT (25%). In multivariable analysis, experiencing ≥1 barrier to BMT was strongly associated with preferring harm reduction agencies (adjusted odds ratio [aOR] = 3.39, 95% confidence interval [CI]: 1.00-11.43). Conclusions: The potential to initiate BMT at harm reduction agencies is highly favorable among harm reduction clients, especially among those experiencing barriers to BMT. Offering BMT at harm reduction agencies could improve access to treatment, but studies are needed to determine safety and efficacy of this approach.

KW - Access to care

KW - buprenorphine

KW - harm reduction agencies

KW - opioid addiction

UR - http://www.scopus.com/inward/record.url?scp=84931351575&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84931351575&partnerID=8YFLogxK

U2 - 10.1080/08897077.2015.1011820

DO - 10.1080/08897077.2015.1011820

M3 - Article

C2 - 25837290

AN - SCOPUS:84931351575

VL - 36

SP - 155

EP - 160

JO - Substance Abuse

JF - Substance Abuse

SN - 0889-7077

IS - 2

ER -